are compound glp-1 safe versions of drugs for weight loss halted by FDA FDA Shares Safety Data About
Description
Incretin-based therapies in obesity-related kidney disease In recent years, studies have been expanded to investigate the effects of incretin-based therapies on kidney outcomes in overweight/obese individuals without T2D

Sultan GLP-1 isnt about perfection

They promote satiety and reduce overall food intake

, Elashoff, R

Naltrexone is approved by the Food and Drug Administration (FDA) to help people stop drinking or cut back on drinking, as well as to reduce alcohol cravings

Free testosterone levels drop significantly during treatment, and these benefits often remain stable even after stopping GLP-1 therapy, provided metformin is continued
